Literature DB >> 22828721

Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activity.

Almoustapha Issiaka Maiga1, Sudhir Penugonda, Drissa Katile, Fodie Diallo, Djeneba Bocar Fofana, Baiba Berzins, Moussa Youssouffa Maiga, Aliou Sylla, Hamar Alassane Traore, Anne-Genevieve Marcelin, Vincent Calvez, Anatole Tounkara, Nobel Bellosillo, Robert Murphy, Babafemi Taiwo.   

Abstract

Mutations in the connection domain (CD) of reverse transcriptase have been implicated in reverse transcriptase inhibitor (RTI) resistance, but this is controversial and little is known in non-B subtype HIV-1. We determined CD mutations prevalence in a population infected predominantly with CRF02_AG and investigated associations with phenotypic RTI resistance. Detected CD mutations were G335D (82.3%), A371V (69.8%), E399D (9.4%), N348I (5.2%), V365I (4.2), Y318F (2.1%), G333E (2.1%), and A360V (2.1%). Mutations were largely polymorphic and did not confer RTI resistance. The observed trend toward reduced likelihood of etravirine or nevirapine resistance in the presence of G335D should be investigated further.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22828721      PMCID: PMC3489470          DOI: 10.1097/QAI.0b013e31826a4b34

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  16 in total

1.  Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.

Authors:  Theresa Pattery; Yvan Verlinden; Hans De Wolf; David Nauwelaers; Kurt Van Baelen; Margariet Van Houtte; Paula Mc Kenna; Jorge Villacian
Journal:  Intervirology       Date:  2012-01-24       Impact factor: 1.763

2.  Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.

Authors:  Atsuko Hachiya; Kazuki Shimane; Stefan G Sarafianos; Eiichi N Kodama; Yasuko Sakagami; Fujie Negishi; Hirokazu Koizumi; Hiroyuki Gatanaga; Masao Matsuoka; Masafumi Takiguchi; Shinichi Oka
Journal:  Antiviral Res       Date:  2009-02-21       Impact factor: 5.970

3.  Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues.

Authors:  Eva Poveda; Carmen de Mendoza; Theresa Pattery; María del Mar González; Jorge Villacian; Vincent Soriano
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

4.  Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance.

Authors:  Galina N Nikolenko; Krista A Delviks-Frankenberry; Sarah Palmer; Frank Maldarelli; Matthew J Fivash; John M Coffin; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-19       Impact factor: 11.205

5.  Connection domain mutations in treatment-experienced patients in the OPTIMA trial.

Authors:  Birgitt Dau; Dieter Ayers; Joel Singer; P Richard Harrigan; Sheldon Brown; Tassos Kyriakides; D William Cameron; Brian Angus; Mark Holodniy
Journal:  J Acquir Immune Defic Syndr       Date:  2010-06       Impact factor: 3.731

6.  Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.

Authors:  Anne-Genevieve Marcelin; Philippe Flandre; Diane Descamps; Laurence Morand-Joubert; Charlotte Charpentier; Jacques Izopet; Mary-Anne Trabaud; Henia Saoudin; Constance Delaugerre; Catherine Tamalet; Jacqueline Cottalorda; Magali Bouvier-Alias; Dominique Bettinger; Georges Dos Santos; Annick Ruffault; Chakib Alloui; Cecile Henquell; Sylvie Rogez; Francis Barin; Anne Signori-Schmuck; Sophie Vallet; Bernard Masquelier; Vincent Calvez
Journal:  Antimicrob Agents Chemother       Date:  2009-11-09       Impact factor: 5.191

7.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

Authors:  L A Kohlstaedt; J Wang; J M Friedman; P A Rice; T A Steitz
Journal:  Science       Date:  1992-06-26       Impact factor: 47.728

8.  Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine.

Authors:  Shannon Zelina; Chih-Wei Sheen; Jessica Radzio; John W Mellors; Nicolas Sluis-Cremer
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

9.  Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.

Authors:  Jessica H Brehm; Dianna Koontz; Jeffrey D Meteer; Vinay Pathak; Nicolas Sluis-Cremer; John W Mellors
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

10.  N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.

Authors:  Soo-Huey Yap; Chih-Wei Sheen; Jonathan Fahey; Mark Zanin; David Tyssen; Viviane Dias Lima; Brian Wynhoven; Michael Kuiper; Nicolas Sluis-Cremer; P Richard Harrigan; Gilda Tachedjian
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

View more
  2 in total

1.  Compensatory role of double mutation N348I/M184V on nevirapine binding landscape: insight from molecular dynamics simulation.

Authors:  Wilson Karubiu; Soumendranath Bhakat; Mahmoud E S Soliman
Journal:  Protein J       Date:  2014-10       Impact factor: 2.371

2.  Identification of Novel Resistance-Related Polymorphisms in HIV-1 Subtype C RT Connection and RNase H Domains from Patients Under Virological Failure in Brazil.

Authors:  Maria F M Barral; Arielly K P Sousa; André F Santos; Celina M Abreu; Amilcar Tanuri; Marcelo A Soares
Journal:  AIDS Res Hum Retroviruses       Date:  2016-12-27       Impact factor: 2.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.